[go: up one dir, main page]

WO2025040354A1 - Composition de produits d'hygiène personnelle - Google Patents

Composition de produits d'hygiène personnelle Download PDF

Info

Publication number
WO2025040354A1
WO2025040354A1 PCT/EP2024/070947 EP2024070947W WO2025040354A1 WO 2025040354 A1 WO2025040354 A1 WO 2025040354A1 EP 2024070947 W EP2024070947 W EP 2024070947W WO 2025040354 A1 WO2025040354 A1 WO 2025040354A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
skin
compound
ascorbyl
carboxymethyl cysteine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2024/070947
Other languages
English (en)
Inventor
Xuelan GU
Zhuang ZHOU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unilever Global IP Ltd
Unilever IP Holdings BV
Conopco Inc
Original Assignee
Unilever Global IP Ltd
Unilever IP Holdings BV
Conopco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever Global IP Ltd, Unilever IP Holdings BV, Conopco Inc filed Critical Unilever Global IP Ltd
Publication of WO2025040354A1 publication Critical patent/WO2025040354A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C

Definitions

  • the present invention relates to a personal care composition
  • a personal care composition comprising carboxymethyl cysteine compound and vitamin C compound selected from ascorbyl glycoside, ascorbyl phosphate, and combination thereof. It was surprisingly found that the level of melanin was inhibited by combining carboxymethyl cysteine compound and such vitamin C compound.
  • Hyperpigmentation which is primarily caused by sunlight, is one of the imperfections that affects the skin appearance in considerable extent. Sunlight comprises harmful UV rays which is one of the main components responsible for hyperpigmentation.
  • One of the ways to address the problem of hyperpigmentation is through cosmetic composition that reduces melanin contents in the skin. The products developed thus far, however, often tend to have low efficacy.
  • the present inventors have acknowledged that there is an increasing interest to develop a personal care composition capable of reducing melanin contents and therefore develop a personal care composition comprising carboxymethyl cysteine compound and vitamin C compound selected from ascorbyl glycoside, ascorbyl phosphate, and combination thereof. It was surprisingly found that such composition is capable of providing improved efficacy of reducing melanin contents.
  • the present invention is directed to a personal care composition
  • a personal care composition comprising carboxymethyl cysteine compound and vitamin C compound selected from ascorbyl glycoside, ascorbyl phosphate, and combination thereof, wherein the carboxymethyl cysteine compound is present in amount of at least 0.00001 % and no greater than 10% by weight of the composition.
  • the present invention is directed to a method of improving the appearance of skin; reducing pigmentation, age spots, melanin contents and/or discoloration of skin; and/or brightening skin comprising a step of topically applying to the skin the composition of the present invention.
  • the present invention is directed to use of composition of the present invention for improving the appearance of skin; reducing pigmentation, melanin contents, age spots and/or discoloration of skin; and/or brightening skin.
  • the carboxymethyl cysteine compound refers to compound selected from carboxymethyl cysteine, salt of carboxymethyl cysteine, ester of carboxymethyl cysteine, amide of carboxymethyl cysteine or a mixture thereof.
  • the carboxymethyl cysteine compound comprises carboxymethyl cysteine, ester of carboxymethyl cysteine, and/or salt of carboxymethyl cysteine.
  • the carboxymethyl cysteine compound comprises carboxymethyl cysteine, and/or salt of carboxymethyl cysteine.
  • carboxymethyl cysteine compound comprises salt of carboxymethyl cysteine.
  • the carboxymethyl cysteine compound comprises lysine carboxymethyl cysteinate and most preferably, the carboxymethyl cysteine compound is lysine carboxymethyl cysteinate.
  • the carboxymethyl cysteine compound is present in amount of at least 0.00001%, more preferably at least 0.0001%, even more preferably at least 0.001%, still even more preferably at least 0.01 %, and most preferably at least 0.1 % by weight of the composition.
  • the carboxymethyl cysteine compound is present in amount of no greater than 10%, more preferably no greater than 5%, even more preferably no greater than 3%, still even more preferably no greater than 1%, and most preferably no greater than 0.5% by weight of the composition.
  • the lysine carboxymethyl cysteinate is present in amount of no greater than 10%, more preferably no greater than 5%, even more preferably no greater than 3%, still even more preferably no greater than 1 %, and most preferably no greater than 0.5% by weight of the composition.
  • the lysine carboxymethyl cysteinate is present in amount of at least 0.00001%, more preferably at least 0.0001 %, even more preferably at least 0.001 %, still even more preferably at least 0.01 %, and most preferably at least 0.1 % by weight of the composition.
  • the composition of the present invention comprises ascorbyl glycoside and/or ascorbyl phosphate.
  • the vitamin C compound is selected from ascorbyl glucoside, sodium ascorbyl phosphate, magnesium ascorbyl phosphate, or mixture thereof. More preferably, the vitamin C compound is ascorbyl glycoside and most preferably the vitamin C compound is ascorbyl glucoside.
  • the composition of the present invention comprises carboxymethyl cysteine compound and ascorbyl glycoside. More preferably the composition of the present invention comprises carboxymethyl cysteine compound and ascorbyl glucoside.
  • the total amount of ascorbyl glycoside and ascorbyl phosphate is 0.0001 to 8% by weight of the composition, more preferably 0.005 to 5% by weight, even more preferably 0.02 to 2% and most preferably 0.1 to 1.2% by weight of the composition.
  • the amount of ascorbyl glycoside is 0.0001 to 8% by weight of the composition, more preferably 0.005 to 5% by weight, even more preferably 0.02 to 2% and most preferably 0.1 to 1.2% by weight of the composition.
  • the amount of ascorbyl glucoside is 0.0001 to 8% by weight of the composition, more preferably 0.005 to 5% by weight, even more preferably 0.02 to 2% and most preferably 0.1 to 1 .2% by weight of the composition.
  • the weight ratio of the lysine carboxymethyl cysteinate to ascorbyl glycoside is 1 :80 to 120:1 , more preferably 1 :30 to 50:1 , even more preferably 1 :15 to 25:1 , still even more preferably 1 :8 to 12:1.
  • the weight ratio of the lysine carboxymethyl cysteinate to ascorbyl glucoside is 1 :80 to 120:1, more preferably 1 :30 to 50:1 , even more preferably 1 :15 to 25:1 , still even more preferably 1:8 to 12:1.
  • the composition may optionally comprise whitening pigment.
  • Whitening pigments are typically particles of high refractive index materials.
  • the whitening pigment may have a refractive index of greater than 1.3, more preferably greater than 1.8 and most preferably from 2.0 to 2.7.
  • Examples of such whitening pigment are those comprising bismuth oxy-chloride, boron nitride, barium sulfate, mica, silica, titanium dioxide, zirconium oxide, aluminium oxide, zinc oxide or combinations thereof. More preferred whitening pigment are particles comprising titanium dioxide, zinc oxide, zirconium oxide, mica, iron oxide or a combination thereof.
  • Even more preferred whitening pigment are particles comprising zinc oxide, zirconium oxide, titanium dioxide or a combination thereof as these materials have especially high refractive index. Still even more preferably the whitening pigment is selected from titanium dioxide, zinc oxide or a mixture thereof and most preferred whitening pigment is titanium dioxide.
  • the average diameter of whitening pigment is typical from 15 nm to 1 micron, more preferably from 35 nm to 800 nm, even more preferably from 50 nm to 500 nm and still even more preferably from 100 to 300 nm.
  • Amount of whitening pigment may be 0.1 to 15%, preferably 0.5 to 5% by weight of the composition.
  • the composition comprises a glutamate source selected from the group consisting of glutamine, glutamine ester, glutamic acid, pyroglutamic acid, salts, and mixtures thereof. More preferably, the composition comprises pyroglutamic acid and/or salt of pyroglutamic acid. Even more preferably, the composition comprises sodium salt of pyroglutamic acid.
  • the glutamate source is present in amount of 0.0001 to 10% by weight of the composition, more preferably 0.001 to 6%, even more preferably 0.01 to 3% by weight of the composition.
  • the composition comprises polyhydric alcohol.
  • Polyhydric alcohols may be selected from group of glycerin, propylyene glycol, dipropylene glycol, polypropylene glycol, polyethylene glycol, sorbitol, hydroxypropyl sorbitol, hexylene glycol, 1 ,3-butylene glycol, isoprene glycol, ethoxylated glycerol, propoxylated glycerol or a mixture thereof. Most preferred polyhydric alcohol is glycerol known also as glycerin.
  • the amount of polyhydric alcohol may range anywhere from 0.1 to 20%, preferably 0.5 to 15% and more preferably 2 and 10% by weight of the composition.
  • the composition comprises emollient materials.
  • Suitable emollient materials include silicones, hydrocarbons, triglycerides or a mixture thereof. These silicones may be organic, silicone-containing or fluorine-containing, volatile or non-volatile, polar or non-polar. Hydrocarbons may include mineral oil, petrolatum and polyalpha-olefins. Examples of preferred volatile hydrocarbons include polydecanes such as isododecane and isodecane (e.g. Permethyl- 99A which is available from Presperse Inc.) and the C7-C8 through C12-C15 isoparaffins (such as the Isopar Series available from Exxon Chemicals).
  • Illustrative triglycerides but not limiting are sunflower seed oil, cotton oil, canola oil, soybean oil, castor oil, borage oil, olive oil, shea butter, jojoba oil and mixtures thereof. Mono- and di- glycerides may also be useful. Particularly preferable are glyceryl monostearate and glyceryl distearate.
  • the composition comprises moisturizing agents.
  • moisturizing agents includes, petrolatum, aquaporin manipulating actives, oat kernel flour, substituted urea like hydroxyethyl urea, hyaluronic acid and/or its precursor N-acetyl glucosamine, hyaluronic acid and/or its precursor N-acetyl glucosamine, or a mixture thereof.
  • compositions may include thickeners. These may be selected from cellulosics, natural gums and acrylic polymers but not limited by this thickening agent types.
  • cellulosics sodium carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose and combinations thereof.
  • Suitable gums include xanthan, pectin, karaya, agar, alginate gums and combinations thereof.
  • acrylic thickeners are homopolymers and copolymers of acrylic and methacrylic acids including carbomers such as Carbopol 1382, Carbopol 982, llltrez, Aqua SF-1 and Aqua SF-2 available from the Lubrizol Corporation.
  • Amounts of thickener may range from 0.01 to 3% by weight of the active polymer (outside of solvent or water) in the compositions.
  • compositions of the invention may further include 0.5 to 10% by weight of sequestering agents, such as tetra sodium ethylenediaminetetraacetate (EDTA), EHDP or mixtures; opacifiers and pearlizers such as ethylene glycol distearate, titanium dioxide or Lytron 621 (Styrene/Acrylate copolymer); all of which are useful in enhancing the appearance or properties of the product.
  • sequestering agents such as tetra sodium ethylenediaminetetraacetate (EDTA), EHDP or mixtures
  • opacifiers and pearlizers such as ethylene glycol distearate, titanium dioxide or Lytron 621 (Styrene/Acrylate copolymer); all of which are useful in enhancing the appearance or properties of the product.
  • the composition may comprise water in amount of 10 to 96% by weight of the composition, more preferably from 25 to 92%, even more preferably from 42 to 88%, most preferably from 55 to 82% by weight of the composition.
  • the composition has a viscosity of at least 10 mPa s, more preferably in the range 30 to 10000 mPa s, even more preferably 50 to 5000 mPa s, and most preferably 100 to 2000 mPa s, when measured at 20 degrees C at a relatively high shear rate of about 20 s' 1 .
  • the composition is an emulsion, more preferably an oil-in-water emulsion.
  • the composition is a fluid liquid at 25 °C and atmospheric pressure.
  • the personal care composition is a skin care composition.
  • Skin care composition refers to a composition suitable for topical application to human skin, including leave-on and wash-off products but preferably leave-on compositions.
  • the term “leave-on” as used with reference to compositions herein means a composition that is applied to or rubbed on the skin, and left thereon.
  • the term “wash-off” as used with reference to compositions herein means a skin cleanser that is applied to or rubbed on the skin and rinsed off substantially immediately subsequent to application.
  • skin as used herein includes the skin on the face, neck, chest, abdomen, back, arms, under arms, hands, and legs.
  • skin means includes the skin on the face and under arms, more preferably skin means skin on the face other than lips and eyelids.
  • the composition is particularly preferably a moisturizer rather than a make-up product.
  • the composition is a topical composition.
  • the composition may be in the form of cream, lotion, ointment, solution, suspension, emulsion, paste, gel, powder, powder foundation, emulsion foundation, wax foundation, or spray. More preferably, the composition may be formulated in the form of cream, lotion, ointment, emulsion, gel, or a spray.
  • the composition is capable of inhibiting melanin by at least 30%, more preferably 35 to 80% most preferably 40 to 70%, typically in comparison to personal care composition comprising neither carboxymethyl cysteine compound nor vitamin C compound selected from ascorbyl glycoside, ascorbyl phosphate, and combination thereof.
  • the use is non-therapeutic.
  • the method is non-therapeutic.
  • non- therapeutic typically means for cosmetic purposes and not curative or therapeutic purposes.
  • NHEM human epidermal melanocytes
  • MGM melanocyte growth medium
  • human melanocyte growth supplement both from Promocell, Germany
  • media was replaced with fresh media containing test samples for the following 72 hours.
  • cell viability was determined using the Cell Counting Kit-8 (CCK8) method (Dojindo, Japan). Briefly, cells were washed once with phosphate buffered saline (PBS) solution. Freshly prepared 300pL of 10 wt% of CCK8 in culture medium was added into each well including the blank control wells without cells. Cells were incubated for 1 hour at 37 °C in the CO2 incubator.
  • PBS phosphate buffered saline
  • the melanin content was calculated from the melanin standard curve.
  • the melanin concentrations (pg/mL) were then normalized to the relative cell viability.
  • the level of actives is based on the amount of medium.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne une composition de produit d'hygiène personnelle contenant un composé de carboxyméthyl cystéine et un composé de vitamine C choisi entre le glycoside d'ascorbyle, le phosphate d'ascorbyle, et une combinaison de ceux-ci ; le composé de carboxyméthyl cystéine étant présent en une quantité comprise entre 0,00001 % et 10 % en poids de la composition.
PCT/EP2024/070947 2023-08-23 2024-07-24 Composition de produits d'hygiène personnelle Pending WO2025040354A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CNPCT/CN2023/114536 2023-08-23
CN2023114536 2023-08-23
EP23201725.1 2023-10-05
EP23201725 2023-10-05

Publications (1)

Publication Number Publication Date
WO2025040354A1 true WO2025040354A1 (fr) 2025-02-27

Family

ID=92106521

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/070947 Pending WO2025040354A1 (fr) 2023-08-23 2024-07-24 Composition de produits d'hygiène personnelle

Country Status (1)

Country Link
WO (1) WO2025040354A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190290575A1 (en) * 2018-03-23 2019-09-26 Mary Kay Inc. Topical compositions and methods
CN113546000A (zh) * 2021-07-05 2021-10-26 北京美丽臻颜化妆品有限公司 一种高稳定性美白护肤品及其制备方法
WO2023126169A1 (fr) * 2021-12-31 2023-07-06 Unilever Ip Holdings B.V. Utilisation d'un composé de carboxyméthylcystéine
WO2023126136A1 (fr) * 2021-12-31 2023-07-06 Unilever Ip Holdings B.V. Composition de soins personnels

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190290575A1 (en) * 2018-03-23 2019-09-26 Mary Kay Inc. Topical compositions and methods
CN113546000A (zh) * 2021-07-05 2021-10-26 北京美丽臻颜化妆品有限公司 一种高稳定性美白护肤品及其制备方法
WO2023126169A1 (fr) * 2021-12-31 2023-07-06 Unilever Ip Holdings B.V. Utilisation d'un composé de carboxyméthylcystéine
WO2023126136A1 (fr) * 2021-12-31 2023-07-06 Unilever Ip Holdings B.V. Composition de soins personnels

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE GNPD [online] MINTEL; 23 February 2021 (2021-02-23), ANONYMOUS: "Conditioner", XP093146425, retrieved from https://www.gnpd.com/sinatra/recordpage/8511505/ Database accession no. 8511505 *

Similar Documents

Publication Publication Date Title
WO2023126169A1 (fr) Utilisation d'un composé de carboxyméthylcystéine
US20250032400A1 (en) Personal care composition
JP4288306B2 (ja) ダイマージリノール酸ジエチレングリコールオリゴマーエステル含有化粧料
JP4178359B2 (ja) 美白化粧料
JP4248366B2 (ja) 敏感肌用のメークアップ
US20140005131A1 (en) Active ingredient combinations of glucosyl glycerides and one or more preservatives
EP4456863B1 (fr) Composition pour soins personnels
WO2025040354A1 (fr) Composition de produits d'hygiène personnelle
JP2005126329A5 (fr)
JP4919547B2 (ja) 美白化粧料
EP4456867A1 (fr) Composition pharmaceutique ou de soins personnels
JP5318395B2 (ja) ダイマージリノール酸ジエチレングリコールオリゴマーエステル含有油性組成物
JP2003252718A (ja) 生体内ジヒドロキシインドール化合物の重合抑制剤
JP4365281B2 (ja) Ｄｆａ含有皮膚外用剤、化粧料、眼科用液剤
JP2005089431A (ja) 角層機能を有するメークアップ化粧料
WO2025040355A1 (fr) Composition de soins personnels
JP5225655B2 (ja) ダイマージリノール酸ジエチレングリコールオリゴマーエステル含有乳化組成物
WO2024099689A1 (fr) Composition de soin personnel
JP5225654B2 (ja) ダイマージリノール酸ジエチレングリコールオリゴマーエステル含有乳化組成物
WO2025002724A1 (fr) Composition de soins personnels comprenant un composé de carboxyméthyl cystéine et un composé de silymarine
JP4842550B2 (ja) チロシナーゼ活性阻害剤、メラニン産生抑制剤及び美白用皮膚外用剤
WO2025002727A1 (fr) Composition de soins personnels
US20230364004A1 (en) Stable compositions containing a cannabinoid
JP2003238328A (ja) 低刺激性皮膚外用剤
WO2025003016A1 (fr) Composition de soins personnels comprenant un composé de carboxyméthylcystéine et un composé de créatine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24748379

Country of ref document: EP

Kind code of ref document: A1